Elevated Levels of Granzyme B Correlated with miR-874-3p Downregulation in Patients with Acute Myocardial Infarction

Yan, Youyou; Song, Xinjing; Li, Zhibo; Zhang, Jinpu; Ren, Jiajun; Wu, Junduo; Li, Yali; Guan, Yinuo; Wang, Junnan

doi:10.2217/bmm-2017-0144

Cited by 16 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 In addition, decreased expression of miR-141 is associated with up-regulation of the RhoA/ROCK pathway in DMED rats. 18 However, the effect of miR-874-3p on DMED remains unknown, and thus the first aim of the current study is to determine the effect of miR-874-3p on erectile dysfunction in male STZ-induced diabetes rats. miR-874-3p, a relatively newly identified miRNA, has been shown to be related to apoptosis and myocardial infarction in patients with acute myocardial infarction when downregulated.…”

Section: Introductionmentioning

confidence: 99%

Epigenetic silencing of microRNA‐874‐3p implicates in erectile dysfunction in diabetic rats by activating the Nupr1/Chop‐mediated pathway

Huo

Zhang

et al. 2019

FASEB j.

View full text Add to dashboard Cite

Diabetes is a global medical problem that causes many deaths every year.Complications caused by diabetes are serious and affect patients' quality of life.Diabetes mellitus erectile dysfunction (DMED) affects more than half of male diabetes patients. In this study, we determined the role of microRNA-874-3p (miR-874-3p) and nuclear protein-1 (Nupr1) in streptozocin-induced DMED rats. Control rats received equal amount of vehicle. These rats were also injected with lentiviral vector or agomir to silence or overexpress miR-874-3p or Nupr1. Apomorphine (100 μg/kg, s.c.) was used to induce erection and time of erection was recorded. Intracavernosal and mean arterial pressure ratio (ICP/MAP) were also recorded. O 2− level and concentration of thiobarbituric acid reactive substances (TBARs) were detected using lucigenin-derived chemiluminescence method and Colorimetry. Rat cavernosum tissues were collected for subsequent experiments. Cavernosum smooth muscle cells (CSMCs) were also used for in vitro experiments. Nupr1 was found highly expressed (by RT-qPCR and Western blot analysis) in cavernosum tissues from DMED rats.Nupr1 silencing improved the ICP/MAP ratio and erection time. Nupr1 silencing also reduced CSMC apoptosis (by TUNEL assay) as well as decreased O 2− level and TBAR concentration. Nupr1 was targeted and inhibited by miR-874-3p (by luciferase activity and RNA immunoprecipitation assays), which was downregulated in DMED. miR-874-3p downregulation was due to increased methylation at the promoter region (methylation-specific PCR). miR-874-3p overexpression improved erection time and reduced apoptosis. In summary, miR-874-3p was downregulated which led to increased apoptosis and erectile dysfunction in DMED rats, through 1696 | HUO et al. | Establishment of STZ-induced DMED rat modelMale specific pathogen-free (SPF) Sprague-Dawley (SD) rats (n = 90, 8 wk old, 250-300 g) that had normal inhibition of Nupr1-mediated pathway. This study may also provide a new therapeutic direction for the treatment of DMED. K E Y W O R D SChop, diabetic erectile dysfunction, microRNA-874-3p, Nupr1

show abstract

Section: Introductionmentioning

confidence: 99%

Epigenetic silencing of microRNA‐874‐3p implicates in erectile dysfunction in diabetic rats by activating the Nupr1/Chop‐mediated pathway

Huo

Zhang

et al. 2019

FASEB j.

View full text Add to dashboard Cite

show abstract

“…126 Therefore, miR-499 could be an important biomarker for MI, especially NSTEMI. 127 Other miR-NAs, such as miR-208, 128 miR-133, 129 miR-1254, 130 miR-99a, 131 miR-122-5p, 132 miR-874-3p, 133 miR-19b, miR-223, and miR-483-5p, 134 also have the potential to predict MI as biomarkers. The potential for lncRNAs to serve as biomarkers of cardiac disease has also been investigated.…”

Section: Rna Molecules Are Potential Targets For Clinical Diagnosis and Gene Therapy For Cardiac Diseasementioning

confidence: 99%

A Roadmap for Fixing the Heart: RNA Regulatory Networks in Cardiac Disease

Tang

Long

Lui

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

With the continuous development of RNA biology and massive genome-wide transcriptome analysis, more and more RNA molecules and their functions have been explored in the last decade. Increasing evidence has demonstrated that RNArelated regulatory networks play an important role in a variety of human diseases, including cardiovascular diseases. In this review, we focus on RNA regulatory networks in heart disease, most of which are devastating conditions with no known cure. We systemically summarize recent discoveries of important new components of RNA regulatory networks, including microRNAs, long non-coding RNAs, and circular RNAs, as well as multiple regulators that affect the activity of these networks in cardiac physiology and pathology. In addition, this review covers emerging micropeptides, which represent short open reading frames (sORFs) in long non-coding RNA transcripts that may modulate cardiac physiology. Based on the current knowledge of RNA regulatory networks, we think that ongoing discoveries will not only provide us a better understanding of the molecular mechanisms that underlie heart disease, but will also identify novel biomarkers and therapeutic targets for the diagnosis and treatment of cardiac disease.ncRNAs Play Important Roles in Heart Disease miRNAs Mediate Post-Transcriptional Regulation of Gene Expression in Heart Disease miRNAs are small, single-stranded ncRNAs with a length of 20-22 nt, which play a crucial role in regulating posttranscriptional gene expression by guiding their target mRNAs to the RNA-induced silencing complex (RISC). 8 Lin-4 of C. elegans was the first

show abstract

“…In addition, elevated levels of miR-19a, miR-22-5p, miR-27a, miR-30a, miR-30a-5p, miR-30d-5p, miR-31, miR-34a, miR-122-5p, miR-125b-5p, miR-133, miR-133b, miR-139-5p, miR-150, miR-181a, miR-195, miR-204, miR-208, miR-208b, miR-221-3p, miR-375, miR-486, miR-497, miR-499a-5p, miR-663b, miR-1291, and let-7b can be potential biomarkers for AMI, increased risk of mortality, or HF (Devaux et al, 2012; Long et al, 2012b; Devaux et al, 2013; Li et al, 2014b; Lv et al, 2014; Peng et al, 2014; Zhong et al, 2014; Han et al, 2015; Yao et al, 2015; Zhang et al, 2015c; Coskunpinar et al, 2016; Jia et al, 2016; Maciejak et al, 2016; O’Sullivan et al, 2016; Zhu et al, 2016; Liu et al, 2017; Zhang and Xie, 2017; Alavi-Moghaddam et al, 2018; Maciejak et al, 2018; Wu et al, 2018a; Wang et al, 2019b). Other potential biomarkers for AMI are downregulated in patients’ plasma, such as miR-99a, miR-122-5p, and miR-874-3p (Yang et al, 2016a; Yan et al, 2017; Wang et al, 2019b). Interestingly, high levels of the combination of miR-21-5p, miR-361-5p, and miR-519e-5p or the reduction of miR-519e-5p correlates with cTnI concentrations, significantly increasing the diagnostic accuracy in AMI patients (Wang et al, 2014b;Liu et al, 2015a).…”

Section: Epigenetic Biomarkers In Cvdsmentioning

confidence: 99%

Epigenetic Biomarkers in Cardiovascular Diseases

2019

View full text Add to dashboard Cite

Cardiovascular diseases are the number one cause of death worldwide and greatly impact quality of life and medical costs. Enormous effort has been made in research to obtain new tools for efficient and quick diagnosis and predicting the prognosis of these diseases. Discoveries of epigenetic mechanisms have related several pathologies, including cardiovascular diseases, to epigenetic dysregulation. This has implications on disease progression and is the basis for new preventive strategies. Advances in methodology and big data analysis have identified novel mechanisms and targets involved in numerous diseases, allowing more individualized epigenetic maps for personalized diagnosis and treatment. This paves the way for what is called pharmacoepigenetics, which predicts the drug response and develops a tailored therapy based on differences in the epigenetic basis of each patient. Similarly, epigenetic biomarkers have emerged as a promising instrument for the consistent diagnosis and prognosis of cardiovascular diseases. Their good accessibility and feasible methods of detection make them suitable for use in clinical practice. However, multicenter studies with a large sample population are required to determine with certainty which epigenetic biomarkers are reliable for clinical routine. Therefore, this review focuses on current discoveries regarding epigenetic biomarkers and its controversy aiming to improve the diagnosis, prognosis, and therapy in cardiovascular patients.

show abstract

Elevated Levels of Granzyme B Correlated with miR-874-3p Downregulation in Patients with Acute Myocardial Infarction

Abstract: Plasma miR-874-3p might target granzyme B and it might be an additional biomarker for AMI.

Cited by 16 publications

References 18 publications

Epigenetic silencing of microRNA‐874‐3p implicates in erectile dysfunction in diabetic rats by activating the Nupr1/Chop‐mediated pathway

Epigenetic silencing of microRNA‐874‐3p implicates in erectile dysfunction in diabetic rats by activating the Nupr1/Chop‐mediated pathway

A Roadmap for Fixing the Heart: RNA Regulatory Networks in Cardiac Disease

Epigenetic Biomarkers in Cardiovascular Diseases

Contact Info

Product

Resources

About